Skip to main content
SpringerLink
Log in

First experience of autologous peripheral blood stem cell mobilization with biosimilar granulocyte colony- stimulating factor

  • Original Research
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Introduction

Mobilization techniques for autologous peripheral blood stem cell (PBSC) collection include chemotherapy followed by hematopoietic growth factors, such as granulocyte colony-stimulating factor (G-CSF). Biosimilar versions of G-CSF are now available in Europe.

Methods

In this study, 40 patients with a hematological malignancy scheduled to receive biosimilar G-CSF (Zarzio® Sandoz Biopharmaceuticals, Paris, France) following first-cycle chemotherapy for treatment and autologous PBSC mobilization were prospectively included at a single center. These patients were compared with a historical control group who had been treated with G-CSF (Neupogen® Paris, France) at the same center according to the same clinical protocol. PBSC harvesting was considered successful if at least 3×106 CD34+ cells/kg were collected. If three consecutive CD34+ tests were below 10/μL then PBSC harvesting was not performed.

Results

Patient characteristics were similar in both groups with no significant differences in age, diagnosis, previous chemotherapy, or chemotherapy mobilization regimen. No significant differences were observed between groups in median CD34+ cells mobilized and collected, or the number of G-CSF injections and leukaphereses required to obtain the minimal CD34+ cell count. Proportion of failures was also similar in both groups.

Conclusion

Zarziois® comparable to Neupogen® for PBSC mobilization and collection after chemotherapy and so may provide a more cost-effective strategy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Child JA, Morgan GJ, Davies FE, et al. Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875–1883.

    Article  PubMed  CAS  Google Scholar 

  2. Pettengell R, Radford JA, Morgenstern GR, et al. Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin’s lymphoma. J Clin Oncol. 1996;14:586–592.

    PubMed  CAS  Google Scholar 

  3. Lefrere F, Makke J, Fermand J, et al. Blood stem cell collection using chemotherapy with or without systematic G-CSF: experience in 52 patients with multiple myeloma. Bone Marrow Transplant. 1999;24:463–466.

    Article  PubMed  CAS  Google Scholar 

  4. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 1991;325:164–170.

    Article  PubMed  CAS  Google Scholar 

  5. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidencebased clinical practice guideline. J Clin Oncol. 2006;24:3187–3205.

    Article  PubMed  CAS  Google Scholar 

  6. Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncol. 2008;19:411–419.

    Article  PubMed  CAS  Google Scholar 

  7. del Giglio A, Eniu A, Ganea-Motan D, Topuzov E, Lubenau H. XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy. BMC Cancer. 2008;8:332.

    Article  PubMed  Google Scholar 

  8. Engert A, Griskevicius L, Zyuzgin Y, Lubenau H, del Giglio A. XM02, the first granulocyte colonystimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy. Leuk Lymphoma. 2009;50:374–379.

    Article  PubMed  CAS  Google Scholar 

  9. Engert A, del Giglio A, Bias P, Lubenau H, Gatzemeier U, Heigener D. Incidence of febrile neutropenia and myelotoxicity of chemotherapy: a meta-analysis of biosimilar G-CSF studies in breast cancer, lung cancer, and non-Hodgkin’s lymphoma. Onkologie. 2009;32:599–604.

    Article  PubMed  CAS  Google Scholar 

  10. Gatzemeier U, Ciuleanu T, Dediu M, Ganea-Motan E, Lubenau H, Del Giglio A. XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinumbased chemotherapy. J Thorac Oncol. 2009;4:736–740.

    Article  PubMed  Google Scholar 

  11. Gascon P, Fuhr U, Sörgel F, et al. Development of a new G-CSF product based on biosimilarity assessment. Ann Oncol. 2010;21:1419–1429.

    Article  PubMed  CAS  Google Scholar 

  12. Lubenau H, Sveikata A, Gumbrevicius G, et al. Bioequivalence of two recombinant granulocyte colony-stimulating factor products after subcutaneous injection in healthy volunteers. Int J Clin Pharmacol Ther. 2009;47:275–282.

    PubMed  CAS  Google Scholar 

  13. Lubenau H, Bias P, Maly AK, Siegler KE, Mehltretter K. Pharmacokinetic and pharmacodynamic profile of new biosimilar filgrastim XM02 equivalent to marketed filgrastim Neupogen: single-blind, randomized, crossover trial. BioDrugs. 2009;23:43–51.

    Article  PubMed  CAS  Google Scholar 

  14. Waller CF, Bronchud M, Mair S, Challand R. Pharmacokinetic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial. Ann Hematol. 2010;89:927–933.

    Article  PubMed  CAS  Google Scholar 

  15. Sörgel F, Lerch H, Lauber T. Physicochemical and biologic comparability of a biosimilar granulocyte colony-stimulating factor with its reference product. BioDrugs. 2010;24:347–357.

    Article  PubMed  Google Scholar 

  16. Skrlin A, Radic I, Vuletic M, et al. Comparison of the physicochemical properties of a biosimilar filgrastim with those of reference filgrastim. Biologicals. 2010;38:557–566.

    Article  PubMed  CAS  Google Scholar 

  17. R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, 2010. Available at: http://www.r-project.org. Accessed March 4, 2011.

  18. Rajkumar SV. Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol. 2011;86:57–65.

    Article  PubMed  Google Scholar 

  19. Niitsu N. Current treatment strategy of diffuse large B-cell lymphomas. Int J Hematol. 2010;92:231–237.

    Article  PubMed  CAS  Google Scholar 

  20. Lefrère F, Zohar S, Ghez D, et al. The VAD chemotherapy regimen plus a G-CSF dose of 10 microg/kg is as effective and less toxic than highdose cyclophosphamide plus a G-CSF dose of 5 microg/kg for progenitor cell mobilization: results from a monocentric study of 82 patients. Bone Marrow Transplant. 2006;37:725–729.

    Article  PubMed  Google Scholar 

  21. Lefrère F, Bernard M, Audat F, et al. Comparison of lenograstim vs filgrastim administration following chemotherapy for peripheral blood stem cell collection: a retrospective study of 126 patients. Leuk Lymphoma. 1999;35:501–505.

    Article  PubMed  Google Scholar 

  22. Perry AR, Watts MJ, Peniket AJ, Goldstone AH, Linch DC. Progenitor cell yields are frequently poor in patients with histologically indolent lymphomas especially when mobilized within 6 months of previous chemotherapy. Bone Marrow Transplant. 1998;21:1201–1205.

    Article  PubMed  CAS  Google Scholar 

  23. Bensinger W, Appelbaum F, Rowley S et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol. 1995;13:2547–2555.

    PubMed  CAS  Google Scholar 

  24. Engelhardt M, Bertz H, Afting M, Waller CF, Finke J. High-versus standard-dose filgrastim (rhG-CSF) for mobilization of peripheral-blood progenitor cells from allogeneic donors and CD34(+) immunoselection. J Clin Oncol. 1999;17:2160–2172.

    PubMed  CAS  Google Scholar 

  25. Vidal. Tarex 2011. Vidal, Issy Les Moulineaux, France, 2011. Available at: http://www.vidal.fr/lesproduits-professionnels/tarex. Accessed March 4, 2011.

Download references

Author information

Authors and Affiliations

  1. Service de Biothérapie, Groupe Hospitalier Necker-Enfants Malades, 149-161 Rue de Sèvres, 75743, Paris Cedex 15, France

    François Lefrère

  2. Service de Biothérapie, H≪tal Necker, APHP, Paris, France

    François Lefrère, Anne-Colette Brignier, Jean-Antoine Ribeil, Michael Bernimoulin, Charbel Aoun, Liliane Dal Cortivo & Marina Cavazzana-Calvo

  3. Service de Biostatique, Hôpital Necker, APHP, Université Paris Descartes, Paris, France

    Caroline Elie

  4. Service d’Hématologie Adultes, H≪tal Necker, APHP, Paris, France

    Richard Delarue & Olivier Hermine

Authors
  1. François Lefrère
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anne-Colette Brignier
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Caroline Elie
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jean-Antoine Ribeil
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Michael Bernimoulin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Charbel Aoun
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Liliane Dal Cortivo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Richard Delarue
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Olivier Hermine
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Marina Cavazzana-Calvo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to François Lefrère.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lefrère, F., Brignier, AC., Elie, C. et al. First experience of autologous peripheral blood stem cell mobilization with biosimilar granulocyte colony- stimulating factor. Adv Therapy 28, 304–310 (2011). https://doi.org/10.1007/s12325-011-0009-1

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-011-0009-1

Keywords

Search

Navigation